Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study
Authors
Jennifer H. Yearley
Sung‐Bae Kim (ORCID: https://orcid.org/0000-0001-5588-8332)
Joohyuk Sohn (ORCID: https://orcid.org/0000-0002-2303-2764)
Javier Cortés (ORCID: https://orcid.org/0000-0001-7623-1583)
Michael Nebozhyn (ORCID: https://orcid.org/0000-0001-8835-7714)
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study
Jennifer H. Yearley, Sung‐Bae Kim, Joohyuk Sohn, Javier Cortés et al.
Citations
4 citations
Journal
Breast Cancer Research
Topics
Cancer Immunotherapy and Biomarkers
Field-Weighted Citation Impact (FWCI)
4.18
article
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study
Jennifer H. Yearley, Sung‐Bae Kim, Joohyuk Sohn, Javier Cortés, Michael Nebozhyn, Rebecca Dent, Peter Schmid, Eva Muñoz‐Couselo, Theodoros Foukakis, Lingkang Huang, Răzvan Cristescu, Seock‐Ah Im, Vassiliki Karantza, Petar Jelinic, Anran Wang, Esther Holgado, Sherko Kümmel, Yeon Hee Park
article en
4 citations
Abstract
No abstract available for this paper.
Publication Tag
Breast Cancer ResearchVol. 27(1)
Institutions
Ulsan College (KR), Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Karolinska University Hospital (SE), Yonsei University (KR), Instituto Cajal (ES), Asan Medical Center (KR), Samsung Medical Center (KR), Seoul National University Hospital (KR), Karolinska Institutet (SE), University of Ulsan (KR), Hospital Quirónsalud Barcelona (ES), Vall d'Hebron Hospital Universitari (ES), National Cancer Centre Singapore (SG), Vall d'Hebron Institute of Oncology (ES), Charité - Universitätsmedizin Berlin (DE), Sungkyunkwan University (KR), Universidad Europea de Madrid (ES)